This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
Dr. Karine Hannebicque has joined our Scientific Advisory Board. She is a surgeon in breast cancer and reconstructive surgery working in Oscar Lambret Center in the Department of breast oncology since 2013. She is also Read more…
We are really happy to welcome Prof. Lo in our Scientific Advisory Board. Prof. Lo has a huge experiment in hepatitis infection and liver diseases with more than 120 publications in this field. With help Read more…
As part of the validation of her Master’s degree in biotechnology (University of Lille), specializing in cellular and molecular engineering, Elise recently joined HCS Pharma. After having completed three internships from one to four months Read more…
Just before Covid-19 pandemic crisis widely spread to France, we attended the User Meeting organized by Molecular Devices in Hilton Garden Inn Leiden (Oegstgeest, Netherlands). We enjoyed the programme, gathering a variety of topics but Read more…
As many companies in France and in the world, the COVID-19 pandemic deeply affects our activities. For safety reasons, most of our work is now done remotely but we maintain essential activity in laboratories to Read more…
Présentation de l’entreprise HCS Pharma est une start-up biotechnologique spécialisée en imagerie cellulaire pour le criblage et l’étude de l’efficacité ou la toxicité de molécules d’intérêt pharmaceutique, cosmétique ou agroalimentaire. Nous développons pour cela nos Read more…
We will give a presentation next week (on Tuesday, 10th of March 2020) at the High-Content Cellular Imaging User meeting organized by our partner Molecular Devices, which will take place in Leiden (Netherlands). It is Read more…
The 8th edition of the Symposium of “Functional Genomics of the Liver” (GFF) will be held from 26 to 28 February 2020 in Rennes, at the Couvent des Jacobins. Meryl, from our team, will be Read more…
Dans le cadre de notre développement, nous recrutons un(e) Technicien(ne) de production en Biomatériaux. Vous serez en charge de réaliser les lots de production : Mettre en œuvre les procédures de production chimiques pour fabriquer des Read more…
It was a real pleasure for us to be invited at the last West Data Festival, to present our last developments in Artificial Intelligence dedicated to picture analysis. We warmly thank the organizers, Laval Mayenne Read more…
We are happy to tell you that HCS Pharma, SMMiL-E team (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer, CNRS UMI-2820 LIMMS/IIS) and Institut d’Electronique, de Micro-Electronique et de Nanotechnologie (IEMN) have Read more…
We often talk about our innovative product BIOMIMESYS® here to explain how we (and others!) us it in many cases. You can imagine that 3D cell culture with this product is complicated or that you Read more…
It is now well described that in tumor biopsies, the stiffness of the cancerous tissue is higher than the surrounding non-cancerous tissue of the same organ, with a described remodeling of the ECM. The increase Read more…
Are you curious about confocal microscopy and the advantages of spinning disk? This article from Teledyne Imaging explains the technology with really simple words. You will understand why we have chosen this way to create Read more…
It will a short article today to wish you a wonderful Christmas and all our best wish for this new year! We don’t known how will be 2020 but we are optimistic : We will Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
This project aims at developing a universal “plug and play” platform, flexible and modular, mimicking the major events occurring in the liver sinusoid: barrier/sieving effect resulting from the specific fenestration of liver sinusoidal endothelial cells, biotransformation and metabolism in the hepatocytes themselves.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.